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tenting or Surgery
n Opportunity to Do it Right*
obert M. Califf, MD, FACC
urham, North Carolina
he publication of two reports (1,2) in this issue of the
ournal concerning the five-year follow-up of randomized
linical trials of percutaneous coronary intervention (PCI)
ith stenting versus coronary artery bypass graft surgery
CABG) is a significant milestone in our understanding of
he evolution of coronary disease treatment. Both of these
tudies represent highly commendable and badly needed
fforts to clarify the data concerning a major life decision for
any people with coronary artery disease. These two studies
n composite show no difference in medium-term (five-year)
See pages 575 and 582
ortality between PCI and CABG and a substantially lower
eed for repeat revascularization in the patients randomly
ssigned to surgery. The studies are discrepant with regard
o nonfatal events, with a clear trend toward a lower
omposite event rate (death, myocardial infarction, or
troke) with surgery in the Arterial Revascularization Ther-
pies Study (ARTS) and no such trend in the Argentine
andomized Trial of Coronary Angioplasty With Stenting
s. Coronary Artery Bypass Surgery in Patients With
ultivessel Disease (ERACI II). Both studies show a
ighly significant difference in repeat revascularization fa-
oring surgery and a more modest benefit of surgery with
egard to angina over time. Interestingly, the ERACI II
tudy found a higher cost per patient over time with an
nitial strategy of PCI.
NTERPRETING RANDOMIZED CLINICAL TRIALS
n the surface, the aforementioned answers appear clear,
ut there are multiple issues to be considered before
eneralizing these findings to routine clinical practice. The
um of these issues relegates these studies to a non-
efinitive, albeit important, addition to our knowledge base.
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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oronary stent manufacturers, including Guidant, Medtronic, and Cordis Inc. The
uke Clinical Research Institute also has contracts with multiple companies that
roduce and sell ancillary medications used in patients undergoing bypass surgery ora
ercutaneous intervention. Dr. Califf receives no personal compensation from any of
hese companies as all research contracts are made with Duke University.Although the effort put into these trials should not be
verlooked, together they include only 137 deaths, an
nsufficient number to detect the modest differences that
ave been identified as clinically meaningful. Therefore, the
imilarity in mortality for the two strategies cannot be
eclared sufficient to conclude that no difference exists,
lthough the potential size of a mortality difference can be
imited to modest magnitude by these findings. Both studies
ere designed to have the power to look at shorter-term
omposite end points and, therefore, were not intended to
rovide a definitive answer on mortality. Despite these
imitations, more studies should consider extending
ollow-up beyond the time specified in the primary end
oint to produce incremental knowledge, as both of these
tudies did.
Additionally, both studies randomly assigned patients
ith relatively less severe forms of multivessel coronary
isease. This decision is understandable because a patient
ad to be suitable for both procedures to be assigned;
ccordingly, 40% to 60% of the patients had two-vessel
isease with well-preserved left ventricular function, and the
edian age (61 to 62 years) was young by today’s standards.
herefore, these results cannot be extended to more severe
orms of disease.
Finally, the high early surgical mortality in the ERACI II
tudy remains a legitimate source of debate. The ERACI II
tudy investigators deserve credit for honestly depicting
heir results. They also have used external comparisons to
ustify the apparently high rate of early mortality in the
urgical group (13 deaths in the first month after surgery,
ith 5 attributed to non-cardiac causes). It appears that the
urgical arm of the ERACI II study had exceedingly bad
uck, and there is reason to worry somewhat about the
uality of the grafts and whether follow-up outcomes
eyond 30 days may have been affected.
NDIVIDUAL DECISION-MAKING
he goals of the biomedical research enterprise should be to
evelop and use technology that prolongs or improves
uman life and to provide the people who will be affected
and their trusted physicians) with the information needed
o make good choices about the use of the technology. No
ne can criticize the ingenuity of the interventional cardi-
logy community in developing new technologies that
enefit patients, but our ability to provide the right circum-
tances for the best decision-making has lagged.
It is likely that most people undergoing coronary angiog-
aphy are not told the entire story when a decision is made
bout undergoing a percutaneous intervention. In most
ircumstances, the patient is referred to a cardiologist, who
oes an angiogram with a plan of placing a coronary stent in
the same sitting.” Cardiologists are growing weary of
ccusations of “self-referral,” but in fact in these settings the
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Editorial Comment August 16, 2005:589–91nancial incentives are lined up in a single direction. Fur-
hermore, once a diagnostic catheterization is completed and
he wheels of revascularization are set in motion, the patient is
n no position to have rational input into the decision, nor is
here an appropriate setting for alternative viewpoints to be
xpressed by cardiac surgeons. Given the large number of cases
oday and the rapid growth expected due to the aging of the
opulation, as well as the emphasis placed on rapid revascu-
arization, it is daunting to consider more time-consuming
pproaches to informing patients, but we must strive to
o so.
HAT ABOUT DRUG-ELUTING STENTS?
n 2003 Hoffman et al. (3) published a systematic overview
f 13 randomized clinical trials comparing percutaneous
ransluminal coronary angioplasty and CABG, demonstrat-
ng a 1.9% survival advantage for CABG over percutaneous
ransluminal coronary angioplasty. However, although
ollow-up was available for only one to three years in the
tent trials, when trials using stents instead of balloon
ngioplasty without stents were compared, the survival
ifference was not evident. One of the concerns about
nterpreting these studies is the possibility that drug-eluting
tents have improved the situation dramatically relative to
are-metal stents. In a manner similar to the impact of
are-metal stents compared with non-stent balloon angio-
lasty, drug-eluting stents further reduce restenosis (4).
owever, they unfortunately appear to have no effect on
eath and nonfatal myocardial infarction relative to bare-
etal stents (5,6). In fact, there is reason for concern that
utside of the setting of clinical trials, the difficulty frequently
ncountered by patients in adhering to thienopyridine treat-
ent regimens exposes them to a risk of abrupt thrombotic
losure, even months after stent implantation (7–9).
During the time since these studies were initiated, coro-
ary bypass surgery procedures have undergone a much less
ighly touted progressive improvement, as evidenced by
etter survival with bypass surgery compared with PCI in a
ecent publication from the Cleveland Clinic (10), and two
dditional reports currently in review from New York State
11) and Duke (Peter Smith, MD, personal communica-
ion, March 11, 2005). Nevertheless, drug-eluting stents
hould mitigate the major difference in the ARTS and
RACI II studies—the need for more repeat revasculariza-
ion procedures after percutaneous intervention. Ongoing
rials should further clarify the divergent information
treams in this comparison.
HOULD IT BE STENTS VERSUS SURGERY?
n an ideal future, cardiologists and cardiac surgeons will
ave a continuous learning mechanism of registries and
rials that will result in more rapid improvement as tech-
ologies and procedures are introduced, evaluated, and 1dopted or discarded. The historical remnants of artificial,
urf-oriented demarcations that deprive patients of optimal
ntegration of practices will be eliminated. Patients and their
amilies will have the opportunity to know the statistics,
oth overall and in the local environment, for therapeutic
ptions so that the choice of procedure will be based on the
eeds of the patient rather than the specialty of the
hysician consulted. Furthermore, the hybrid procedure will
ikely eventually be a realistic expectation; many patients could
enefit from an internal thoracic artery implant to the left
nterior descending artery with stenting of other vessels (12).
Until that ideal world is reached, we should strive within
ur microenvironments to develop quality-measurement
ystems, participate in clinical research that defines quality,
nd adapt practice to integrate new findings as they evolve.
ur patients deserve to hear the full, unbiased story as they
ake these life-changing decisions about coronary revascu-
arization. For that to happen, we need more information of
he type produced by the ERACI II and ARTS studies, and
t will need to come at a faster rate. We also need to
e-engineer the clinical enterprise so that such important
ecisions are made in the most informed manner possible,
hile maintaining consistency with the sensibilities and
references of the patient.
eprint requests and correspondence: Dr. Robert M. Califf,
uke Clinical Research Institute, PO Box 17969, Durham, North
arolina 27715. E-mail: calif001@mc.duke.edu.
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